Literature DB >> 22037472

Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.

Chuan Shen1, Rameen Beroukhim, Steven E Schumacher, Jing Zhou, Michelle Chang, Sabina Signoretti, William G Kaelin.   

Abstract

UNLABELLED: Kidney cancers often delete chromosome 3p, spanning the VHL tumor suppressor gene, and chromosome 14q, which presumably harbors ≥ 1 tumor suppressor genes. pVHL inhibits the hypoxia-inducible transcription factor (HIF), and HIF2α is a kidney cancer oncoprotein. In this article, we identify focal, homozygous deletions of the HIF1α locus on 14q in clear cell renal carcinoma cell lines. Wild-type HIF1α suppresses renal carcinoma growth, but the products of these altered loci do not. Conversely, downregulation of HIF1α in HIF1α-proficient lines promotes tumor growth. HIF1α activity is diminished in 14q-deleted kidney cancers, and all somatic HIF1α mutations identified in kidney cancers tested to date are loss of function. Therefore, HIF1α has the credentials of a kidney cancer suppressor gene. SIGNIFICANCE: Deletion of 14q is a frequent event in clear cell renal carcinoma and portends a poor prognosis. In this study, we provide genetic and functional evidence that HIF1α is a target of 14q loss in kidney cancer.

Entities:  

Keywords:  14q deletion; HIF1α; hypoxia; kidney cancer; tumor suppression; von Hippel-Lindau

Mesh:

Substances:

Year:  2011        PMID: 22037472      PMCID: PMC3202343          DOI: 10.1158/2159-8290.CD-11-0098

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  54 in total

Review 1.  LOT1 (ZAC1/PLAGL1) and its family members: mechanisms and functions.

Authors:  Abbas Abdollahi
Journal:  J Cell Physiol       Date:  2007-01       Impact factor: 6.384

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.

Authors:  Toshiaki Shinojima; Mototsugu Oya; Atsushi Takayanagi; Ryuichi Mizuno; Nobuyoshi Shimizu; Masaru Murai
Journal:  Carcinogenesis       Date:  2006-08-18       Impact factor: 4.944

4.  Downregulation of metastasis suppressor genes in malignant pheochromocytoma.

Authors:  Shoichiro Ohta; Edwin W Lai; Alan L Y Pang; Frederieke M Brouwers; Wai-Yee Chan; Graeme Eisenhofer; Ronald de Krijger; Lucia Ksinantova; Jan Breza; Pavel Blazicek; Richard Kvetnansky; Robert A Wesley; Karel Pacak
Journal:  Int J Cancer       Date:  2005-03-10       Impact factor: 7.396

Review 5.  The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network.

Authors:  Kieran Harvey; Nicolas Tapon
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

6.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice.

Authors:  Erinn B Rankin; Jennifer Rha; Travis L Unger; Chia H Wu; Heather P Shutt; Randall S Johnson; M Celeste Simon; Brian Keith; Volker H Haase
Journal:  Oncogene       Date:  2008-05-19       Impact factor: 9.867

8.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 9.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

10.  Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts.

Authors:  Swethajit Biswas; Helen Troy; Russell Leek; Yuen-Li Chung; Ji-Liang Li; Raju R Raval; Helen Turley; Kevin Gatter; Francesco Pezzella; John R Griffiths; Marion Stubbs; Adrian L Harris
Journal:  J Oncol       Date:  2010-06-27       Impact factor: 4.375

View more
  183 in total

1.  Untuning the tumor metabolic machine: HIF-α: pro- and antitumorigenic?

Authors:  Regina M Young; M Celeste Simon
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

2.  A Three-microRNA Panel in Serum: Serving as a Potential Diagnostic Biomarker for Renal Cell Carcinoma.

Authors:  Guocheng Huang; Xinji Li; Zebo Chen; Jingyao Wang; Chunduo Zhang; Xuan Chen; Xiqi Peng; Kaihao Liu; Liwen Zhao; Yongqing Lai; Liangchao Ni
Journal:  Pathol Oncol Res       Date:  2020-06-18       Impact factor: 3.201

Review 3.  Oncogenes strike a balance between cellular growth and homeostasis.

Authors:  Bo Qiu; M Celeste Simon
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

Review 4.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

5.  HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.

Authors:  Abhishek A Chakraborty; Eijiro Nakamura; Jun Qi; Amanda Creech; Jacob D Jaffe; Joshiawa Paulk; Jesse S Novak; Kshithija Nagulapalli; Samuel K McBrayer; Glenn S Cowley; Javier Pineda; Jiaxi Song; Yaoyu E Wang; Steven A Carr; David E Root; Sabina Signoretti; James E Bradner; William G Kaelin
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

6.  Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.

Authors:  Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon
Journal:  Cell Metab       Date:  2018-05-10       Impact factor: 27.287

7.  DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia.

Authors:  Gabriel Lachance; James Uniacke; Timothy E Audas; Chet E Holterman; Aleksandra Franovic; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

Review 8.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

9.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 10.  Metabolism of kidney cancer: from the lab to clinical practice.

Authors:  Sunil Sudarshan; Jose A Karam; James Brugarolas; R Houston Thompson; Robert Uzzo; Brian Rini; Vitaly Margulis; Jean-Jacques Patard; Bernard Escudier; W Marston Linehan
Journal:  Eur Urol       Date:  2012-09-28       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.